Background Endothelin (ET)-1 has potent vascular effects. Two endothelin receptors have been cloned, namely, the ETA receptor, which preferentially binds ET-1, and the ETB receptor, which equally binds ET-1 and ET-3 and preferentially sarafotoxin S6c. We characterized endothelin receptor subtypes on vascular smooth muscle and endothelium of isolated human internal mammary artery (IMA) and vein (IMV) and porcine coronary artery (PCA) using the ETA antagonists FR139317 and BQ-123, the ETB ligand sarafotoxin S6c, and the ETA/ETB antagonist Ro 47-0203 (bosentan).
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Methods and Results In endothelium-denuded IMA and PCA and less so in IMV, FR139317 and BQ-123 (in PCA only) shifted the concentration-contraction curves to ET-1 parallel to the right. However, even at 10`mol/L, FR139317 did not inhibit a high-sensitivity portion of the concentration-contraction curve. Moreover, the ETB receptor agonist sarafotoxin S6c induced contraction in vessels preincubated with FR139317. IMV was significantly more sensitive to the contractile effect of ET-1 and sarafotoxin S6c than was IMA (P<.05). Prolonged E _ ndothelin (ET)-1 is a 21-amino acid peptide that has strong vasoconstrictor'-3 as well as mitogenic activity. 4 In addition, under certain conditions it can cause vasodilation5: Its plasma levels are very low in normal subjects but are augmented in many disease states such as in certain patients with hypertension,67 atherosclerosis,8 acute myocardial infarction,9 and renal failure,10 suggesting that it may play a pathophysiological role in these situations.
Three isoforms of endothelin (ET-1, ET-2, ET-3) are known,'" but only ET-1 is produced by the vascular endothelium. Two 
Effect of Sarafotoxin S6c on FR139317-Resistant Portion of the Concentration-Contraction Curves to ET-I (Protocol 2)
Concentration-contraction curves to ET-1 revealed a portion resistant to FR139317 in IMA, IMV, and PCA (see below). To examine whether this was due to ETB receptor activation, some vessels were preincubated with sarafotoxin S6c (3 X 10`mol/L) for 1 hour (to downregulate ETB receptors) and then with FR139317 (10-5 mol/L) for additional 30 minutes. Concentration-contraction curves to ET-1 were constructed for control vessels, vessels preincubated with FR139317, and those preincubated with sarafotoxin S6c and FR139317.
Contractions to Sarafotoxin S6c (Protocol 3)
To test the presence of ETB receptors, rings were preincubated with FR139317 (10`mol/L) for 30 minutes (to block ETA receptors), and cumulative concentration-contraction curves to sarafotoxin S6c were constructed.
Effect of a Combined ETAIETB Receptor Antagonist Bosentan on Contractions to ET-I (Protocol 4)
In IMA rings preincubated with bosentan (10`mol/L, 10-6 mol/L, 10`mol/L, 30 minutes), concentration-contraction curves to ET-1 were constructed. Endothelium was not removed in this protocol because protocol 5 (below) showed that endothelium of IMA did not cause endothelium-dependent relaxation (see "Results").
Effect of Sarafotoxin S6c in Rings With Endothelium (Protocol 5)
To examine whether ETB receptor stimulation causes endothelium-dependent relaxation, rings were precontracted with norepinephrine (3 x 10`7mol/L in IMA, 10 mol/L in IMV) or acetylcholine (3 x 10 mol/L in PCA) and exposed to cumulative concentrations of acetylcholine (IMA) or bradykinin (IMV and PCA), respectively. Rings then were washed, preincubated with FR139317 (10-5 mol/L, 30 minutes), and cumulative concentration-response curves to sarafotoxin S6c were constructed under the same conditions as above.
Since sarafotoxin S6c did not relax in IMA or PCA (see "Results"), the same protocol was performed after preincubation of these vessels with indomethacin (10`mol/L, to inhibit possible release of cyclooxygenase-derived endothelium-derived contracting factor6) and FR139317 for 30 minutes.
Detection of mRNA for ETB Receptor Preparation of RNA Total RNA was extracted from IMA or aorta by homogenizing the frozen tissue in 4 mol/L guanidine thiocyanate buffer, layering over a 5.6 mol/L CsCl-25 mmol/L sodium acetate cushion, and centrifuging at 175 000g for 24 to 36 hours23 or by phenol-chloroform extraction according to the single-step method described by Chomczynski and Sacchi.24 Poly(A)+ RNA was purified by two cycles of selection on an oligo(dT) cellulose column (Pharmacia).
Northern Blot Analysis
RNAs were prepared from aorta of organ donor patients or IMA of patients undergoing coronary bypass surgery. Approximately 5 ,g of poly(A)+ RNA was subjected to electrophoresis on 1% formaldehyde-agarose gels and transferred to Hybond-N filters (Amersham). The filters were hybridized in 0.5 mol/L Na2PO4 (pH 7.2), 1% bovine serum albumin, 7% SDS, and 10 mmol/L EDTA at 65°C with the 32P-labeled cDNA probe prepared by random prime labeling and washed in 2xSSC, 0.1% SDS-0.1xSSC, 0.1% SDS at 65°C. Filters were hybridized with a 0.4-kb ETA receptor cDNA probe or a 1.4-kb ETB receptor cDNA (both generous gifts of Dr T. Sakurai, University of Tsukuba, Japan) and as control with a 1.9-kb EcoRI fragment of human f3-actin cDNA probe. Membranes were exposed to Kodak XRP x-ray film using an intensifying screen at -70°C for 24 hours.
Drugs
The following drugs were used (all from Sigma Chemical Co, St Louis, Mo, unless otherwise stated): ET-1 and FR139317 (Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan); sarafotoxin S6c (Bachem, Bubendorf, Switzerland); acetylcholine, bradykinin, norepinephrine, indomethacin, and bosentan (F. Hoffmann-La Roche, Ltd, Basel, Switzerland). ET-1 and sarafotoxin S6c were dissolved in 0.1% bovine serum albumin.
FR139317 was dissolved in 50% ethanol (stock solution, 10-5 mol/L) and diluted with distilled water. The final concentration of ethanol in the organ chamber was less than 0.3%.
Indomethacin was dissolved in distilled water containing 5x 10-3 mol/L carbonate. All other drugs were dissolved in distilled water.
Data Analysis and Statistics
Contractions are expressed as a percentage of the control response to 100 mmol/L KCl. In protocol 1, the concentration of ET-1 (expressed as negative log molar) exhibiting 50% of the response to 100 mmol/L KCl (pD2) was calculated separately for each ring. The area under the concentration-contraction curves (in arbitrary units) also was response was even more pronounced in the IMV at concentrations of 10`13 to 10`8 mol/L ET-1 (Fig 2) .
Effect of Sarafotoxin S6c in Quiescent Vessels
Certain quiescent vessels were preincubated with sarafotoxin S6c (in the presence of 10`mol/L FR139317). Under these conditions, sarafotoxin S6c (3 x10-7 mol/L) induced immediate contractions in all vessels (27+12% of KCI 100 mmol/L in IMA, 106±4% in IMV, 61±19% in PCA), which decreased spontaneously, and only a small contraction (2±1% in IMA, 4±2% in IMV, 21±5% in PCA) was left after 1 hour.
Readdition of sarafotoxin S6c did not cause contraction after this incubation. If concentration-contraction curves to ET-1 were performed after preincubation of the vessels with sarafotoxin S6c, the portion of the endothelin-induced contraction resistant to FR139317 was suppressed in IMA and IMV (Fig 2) . Similar results were obtained in PCA (n=6, data not shown).
In the presence of FR139317 (10 mol/L), sarafotoxin S6c evoked concentration-dependent contractions in IMA, IMV, and PCA (Fig 3) . The maximal contraction was greater and the area under the curve larger in IMV than IMA (P<.05; pD2 in IMV, 9.0±0.3; IMA was not calculable). Maximal contraction of PCA to sarafotoxin S6c also was more pronounced than that of IMA (P<.05; Fig 3; pD2, 8.6±0.1) . Effects of Bosentan on Contraction to ET-1
In IMA, bosentan shifted the concentration-contraction curves to the right in a completely parallel fashion, contrary to the case of FR139317 (Fig 4) . The pD2 values of ET-1 were 8.3±0.1 under control conditions and 8.3 ± 0.1 (10 mol/L), 7.9 ± 0.1 (10-6 mol/L, P<c.05), and 7.2±0.1 (10`mol/L, P<.05) in the presence of bosentan.
Northern Blot Analysis ETB receptor mRNA was detected in IMA as well as in aortic smooth muscle cells (Fig 5) . Endothein-1 (-log M) 
Effect of Sarafotoxin S6c in Precontracted Vessels With Endothelium
In IMA, IMV, and PCA with endothelium contracted with norepinephrine or acetylcholine, respectively, acetylcholine (IMA) or bradykinin (IMV and PCA) exhibited potent relaxation, demonstrating the presence of endothelium (n=5; IC50 in IMA, 7 The fact that vasoconstrictor ETB receptors are present in human mammary arteries and veins as well as in PCA has important implications for drug development and therapeutic use of endothelin antagonists in patients. Indeed, to prevent endothelin-induced responses, a combined ETA/ETB antagonist such as bosentan is required, particularly at lower concentrations of endothelin (which are more likely to be achieved in vivo6). The results obtained in PCA, which was used as a model for the human coronary artery, suggest that ETB receptors also contribute to contractile responses in the coronary circulation and that activation of these receptors may be involved in coronary spasm40 and extension of myocardial infarction.30 As the contraction to sarafotoxin S6c was much larger in mammary veins than in arteries, ETB receptors may be especially important in the venous system. The increased sensitivity of veins2 is related to a larger contribution of ETB receptors. Circulating endothelin levels are higher in venous than in arterial blood40 and are increased in heart failure,41 a clinical syndrome with excess venous tone. If ETB receptors -as suggested by our preliminary results with IMA resistance arteries -also contribute to peripheral vascular resistance, combined endothelin antagonists will give more insights into the role of endothelin in hypertension (see References 6 and 42) . A potential disadvantage of combined ETA/ETB receptor antagonist may be blockade of nitric oxide or prostacyclin release in certain blood vessels."3'5 However, the fact that such molecules fully block the vasoconstrictor effect of ET-1 appears to be more important.
